Medicine · 2026
Bezafibrate-associated rhabdomyolysis in a patient with diabetic kidney disease: A case report and successful transition to tafolecimab.
СтатьяКлинический случайНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Zhang Yiping, Wang Jinrong, Xie Xiaohong, Gu Wei
Аннотация
RATIONALE: Fibrates like bezafibrate are renally excreted and can cause rhabdomyolysis in chronic kidney disease (CKD). This report describes bezafibrate-associated rhabdomyolysis in a patient with diabetic kidney disease and successful transition to tafolecimab.
PATIENT CONCERNS: Ten days after self-initiating bezafibrate (0.2 g thrice daily), a 71-year-old female patient with diabetes, hypertension, CKD, and dyslipidemia complained of fatigue, sweating, and myalgia. Tests revealed hypokalemia, renal failure (creatinine 329.3 μmol/L), and increased creatine kinase (4865 U/L).
DIAGNOSES: After ruling out other causes, a peak creatine kinase of 6419 U/L (38× upper normal limit) and myalgia were used to diagnose bezafibrate-associated rhabdomyolysis.
INTERVENTIONS: The use of bezafibrate was stopped. Hepatoprotection, renal protection, bicarbonate, potassium correction, and eventually a switch to subcutaneous tafolecimab 150 mg every 2 weeks were all part of the supportive care.
OUTCOMES: Myalgia went away in 6 days, and by the time of discharge, creatine kinase had returned to normal from 6419 to 54 U/L. Following tafolecimab, low-density lipoprotein cholesterol (4.18 to 2.93 mmol/L) was lower, and muscle enzymes were normal.
LESSONS: Bezafibrate may result in severe rhabdomyolysis in diabetic CKD, particularly when combined with nifedipine (a CYP3A4 inhibitor) and reduced renal clearance. Tafolecimab's nonrenal metabolism and low myotoxicity make it a safe and efficient substitute.
PATIENT CONCERNS: Ten days after self-initiating bezafibrate (0.2 g thrice daily), a 71-year-old female patient with diabetes, hypertension, CKD, and dyslipidemia complained of fatigue, sweating, and myalgia. Tests revealed hypokalemia, renal failure (creatinine 329.3 μmol/L), and increased creatine kinase (4865 U/L).
DIAGNOSES: After ruling out other causes, a peak creatine kinase of 6419 U/L (38× upper normal limit) and myalgia were used to diagnose bezafibrate-associated rhabdomyolysis.
INTERVENTIONS: The use of bezafibrate was stopped. Hepatoprotection, renal protection, bicarbonate, potassium correction, and eventually a switch to subcutaneous tafolecimab 150 mg every 2 weeks were all part of the supportive care.
OUTCOMES: Myalgia went away in 6 days, and by the time of discharge, creatine kinase had returned to normal from 6419 to 54 U/L. Following tafolecimab, low-density lipoprotein cholesterol (4.18 to 2.93 mmol/L) was lower, and muscle enzymes were normal.
LESSONS: Bezafibrate may result in severe rhabdomyolysis in diabetic CKD, particularly when combined with nifedipine (a CYP3A4 inhibitor) and reduced renal clearance. Tafolecimab's nonrenal metabolism and low myotoxicity make it a safe and efficient substitute.